Su‐Mi Choi, Jeong Hyun Heo, Yeseul Kim, JinWoo Hong, Sieun Lee, Tae Woo Oh, Suhyun Park, Minsu Gu, Seung‐Woo Cho, Yoonhee Jin, Su‐Hwan Kim
Hypoxia contributes to a wide range of pathological conditions, including muscle atrophy and ischemic diseases, yet effective therapeutic strategies remain limited. In this study, we developed an epigallocatechin-3-gallate (EGCG)–catalase complex (EC) that simultaneously provides oxygenation and reactive oxygen species (ROS) clearance through multienzyme mimicry. EC exhibits superoxide dismutase (SOD)-like activity by converting superoxide anion (O 2 •– ) into hydrogen peroxide (H 2 O 2 ), followed by catalase-mediated decomposition of H 2 O 2 into oxygen (O 2 ) and water (H 2 O), thereby transforming harmful ROS into beneficial O 2 . In addition, EC employs peroxidase (POD)- and glutathione peroxidase (GPx)-like pathways to further eliminate residual H 2 O 2, establishing a cascade antioxidative defense system. At the cellular level, EC modulated hypoxia-inducible factor-1 alpha (HIF-1α) expression, promoted angiogenesis, and enhanced myogenic differentiation. In vivo, EC improved muscle regeneration and functional recovery in a dexamethasone-induced atrophy model, while promoting angiogenesis and suppressing fibrosis in a diabetic hindlimb ischemia model. Collectively, these findings highlight EC as an integrated therapeutic platform that combines O 2 supply with ROS regulation via multienzyme mimicry, offering promising potential for the treatment of hypoxia-associated diseases.